NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.



Don't have an account? Register

ADVERTISEMENT

ADVERTISEMENT

Controlling gabapentinoids under examination

By Mindo - 04th Jun 2021

Close-up of foil-material medicine pill package production line.

The Department of Health is engaged in a process to determine whether gabapentinoids should be scheduled as controlled drugs, the Medical Independent (MI) has been informed.

A Department spokesperson told MI: “The Health Products Regulatory Authority and the Department of Health are in ongoing discussions in relation to potential for misuse or abuse of gabapentinoids. Data is being gathered on the matter before considering whether to recommend the scheduling of gabapentinoids as controlled substances.”

In a recent interview with MI, the then Medical Council President Dr Rita Doyle said pregabalin and gabapentin should be made controlled drugs in Ireland. She said addiction to pregabalin is a “huge” issue in this country.

Pregabalin, also known by the brand name Lyrica, is licenced for use in epilepsy, generalised anxiety disorder, and peripheral and central neuropathic pain. Gabapentin, also known by the brand name Neurontin, is licenced for epilepsy and peripheral neuropathic pain.

Dr Doyle noted that pregabalin and gabapentin had been made controlled drugs in the UK “and I certainly foresee that will happen here”. An over-prescribing working group at the Medical Council is also discussing prescription of opioids in Ireland.

Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
Medical Independent 5th November
Medical Independent 5th November 2024

You need to be logged in to access this content. Please login or sign up using the links below.

ADVERTISEMENT

Trending Articles

ADVERTISEMENT